title: Modulation of types I and II acute phase reactants with insulin-like growth factor-1/binding protein-3 complex in severely burned children.
abstract: OBJECTIVE
  To determine whether 0.5 mg/kg insulin-like growth factor (IGF)-1/binding protein (IGFBP)-3, given intravenously, effectively alters the acute phase response in severely burned children.
  
  
  METHODS
  Longitudinal trial with each patient serving as their own control.
  
  
  METHODS
  University-affiliated pediatric bum center.
  
  
  METHODS
  Nine children, 15 yrs of age or less, with burns covering >40% of the total body surface area.
  
  
  METHODS
  Standard burn care with early burn wound excision and grafting. Blood sampled at defined time points before and after operative procedures.
  
  
  RESULTS
  Determination of types I and II acute phase reactant proteins, constitutive serum proteins, serum cytokines, serum IGF-1, IGFBP-3, and growth hormone levels. Treatment with IGF-1/BP-3 attenuated increases in type I (complement 3, alpha1-acidglycoprotein) and type II (haptoglobin, alpha1-antitrypsin) acute phase proteins. Further, IGF-1/BP-3 increased constitutive serum protein levels (prealbumin, retinol binding protein, transferrin) and decreased serum IL-6 levels.
  
  
  CONCLUSIONS
  Low-dose IGF-1/BP-3 effectively attenuated the type I and type II hepatic acute phase response, increased serum levels of constitutive proteins, and modulated the hypermetabolic response.
authors.affiliation: Shriners Hospital for Children and Department of Surgery, The University Texas Medical Branch, Galveston 77550, USA.
authors.forename: Marcus
authors.initials: M
authors.lastname: Spies
authors.forename: Steven E
authors.initials: SE
authors.lastname: Wolf
authors.forename: Robert E
authors.initials: RE
authors.lastname: Barrow
authors.forename: Marc G
authors.initials: MG
authors.lastname: Jeschke
authors.forename: David N
authors.initials: DN
authors.lastname: Herndon
mesh_terms: D000209:Acute-Phase Proteins / Q000378:metabolism*; D002056:Burns / Q000097:blood / Q000188:drug therapy*; D002675:Child, Preschool; D003176:Complement C3 / Q000032:analysis; D016207:Cytokines / Q000097:blood; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006242:Haptoglobins / Q000032:analysis; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000008:administration & dosage* / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage* / Q000032:analysis; D008137:Longitudinal Studies; D008297:Male; D009961:Orosomucoid / Q000032:analysis; D011228:Prealbumin / Q000032:analysis; D012177:Retinol-Binding Proteins / Q000032:analysis; D014168:Transferrin / Q000032:analysis; D000515:alpha 1-Antitrypsin / Q000032:analysis
chemical_list: D000209:Acute-Phase Proteins; D003176:Complement C3; D016207:Cytokines; D006242:Haptoglobins; D018972:Insulin-Like Growth Factor Binding Protein 3; D009961:Orosomucoid; D011228:Prealbumin; D012177:Retinol-Binding Proteins; D014168:Transferrin; D000515:alpha 1-Antitrypsin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone